Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Medicxi is a European investment firm established in 2016 as a spin-out from Index Ventures Life Sciences. The firm was founded by a team with over 20 years of experience in drug discovery and therapeutic development. Medicxi is currently investing from its latest fund, Medicxi IV, while also managing the Index Ventures life sciences portfolio. The firm has raised a total of over €2 billion across six funds, with notable investors including GlaxoSmithKline, Johnson & Johnson Innovation, Novartis, and Verily, an Alphabet company.
Headquartered in London, Medicxi also has offices in Geneva, Switzerland, and St. Helier, Jersey. The firm focuses on addressing unmet medical needs through investments in the life sciences sector, particularly in biotech and healthcare. Medicxi has achieved significant milestones, including successful exits with companies like Vaxcyte and Merus, both of which went public. The firm emphasizes an asset-centric financing model that supports early-stage innovation and minimizes governance complexities.
Medicxi invests primarily in the life sciences sector, concentrating on biotech companies throughout the drug development continuum. The firm targets early-stage companies that have achieved clinical proof-of-concept and are preparing for pivotal studies and regulatory approvals. Medicxi employs an asset-centric financing model, which allows for a streamlined approach to governance and decision-making, enabling founders to focus on their product visions.
The firm typically invests in companies at various stages, including pre-seed, seed, Series A, Series B, and Series C. Medicxi's check sizes vary, aligning with the specific needs of the companies it supports. The firm’s investment strategy is designed to back ventures that are poised to develop their compounds independently, ensuring that they have the necessary resources and guidance to navigate the complexities of drug development.
Medicxi's portfolio includes several notable companies in the biotech and healthcare sectors. Key investments include:
Medicxi has also seen successful exits with several companies:
Francesco De Rubertis - Partner. He is a founding partner from the Index Ventures days and has extensive experience in life sciences investments.
Giovanni Mariggi, PhD - Partner. He brings a strong scientific background and has been involved in various successful biotech ventures.
Nick Williams - Partner. He has a proven track record in the biotech sector and focuses on strategic investments.
Shyam Masrani - Partner. Recently promoted with Fund V, he has significant experience in drug development and investment.
Richard Lee - Partner. He has a strong background in life sciences and has led several successful investments.
Giovanni Pericolini - Partner. He contributes extensive industry knowledge and investment experience.
Victoria Taylor - Investment Team. She supports the investment process with a focus on biotech.
Francois Prinsloo - Investment Team. He has a background in life sciences and contributes to deal sourcing and evaluation.
Freya Svedberg-Keating - Investment Team. She focuses on supporting portfolio companies and investment analysis.
David Grainger - Investment Team. He has experience in biotech investments and supports the firm's strategic initiatives.
Moncef Slaoui - Investment Team. He is known for his expertise in drug development and regulatory affairs.
Thibaut De Smedt - Investment Team. He contributes to the firm's investment strategy and portfolio management.
Ben Perry - Investment Team. He focuses on evaluating new investment opportunities in biotech.
Mehdi Shahidi - Investment Team. He has a strong background in life sciences and supports the investment process.
Charles Grummitt - Investment Team. He contributes to deal sourcing and portfolio management.
Stephen Rapecki - Investment Team. He focuses on supporting portfolio companies and investment analysis.
Marco Prunotto - Investment Team. He has experience in biotech investments and supports the firm's strategic initiatives.
João Vieira - Investment Team. He contributes to the firm's investment strategy and portfolio management.
Thibaud Portal - Investment Team. He focuses on evaluating new investment opportunities in biotech.
Rémy Luthringer - Investment Team. He has a strong background in life sciences and supports the investment process.
Trevor Baglin - Investment Team. He focuses on supporting portfolio companies and investment analysis.
Michèle Ollier - Investment Team. She has experience in biotech investments and supports the firm's strategic initiatives.
Kevin Johnson - Investment Team. He contributes to deal sourcing and portfolio management.
Giuseppe Zocco - Investment Team. He focuses on evaluating new investment opportunities in biotech.
Giles Johnstone-Scott - Operations Team. He supports the operational aspects of the firm.
Sylvia Elder - Operations Team. She contributes to the firm's operational efficiency.
Philip Brown - Operations Team. He focuses on supporting the firm's operational needs.
Andrew Jeanne - Operations Team. He contributes to the operational management of the firm.
Natalie Bougourd - Operations Team. She supports the firm's operational functions.
Marie Beaucourt - Operations Team. She focuses on enhancing the firm's operational capabilities.
Nina Moir - Operations Team. She contributes to the operational management of the firm.
Sarah Toulouse - Operations Team. She supports the firm's operational needs.
Florence Liaigre - Operations Team. She focuses on enhancing the firm's operational capabilities.
Charline Gesbert - Operations Team. She contributes to the operational management of the firm.
Startups interested in pitching to Medicxi should send their proposals via email to investor@medicxi.com. It is essential to include a comprehensive pitch deck that outlines the startup's vision, product development stage, and market opportunity. Medicxi prefers detailed presentations that highlight the clinical proof-of-concept and the strategic plan for regulatory approval.
Response times may vary, but founders can generally expect feedback within a few weeks. Warm introductions are beneficial, as they can facilitate a more favorable review process. Startups should ensure that their pitch clearly communicates their unique value proposition and the specific milestones they aim to achieve.
In 2025, Medicxi closed its Fund V, raising approximately €500 million ($581 million) to continue its focus on asset-centric biotech investments. This fund is actively deploying capital into promising life sciences ventures.
Recently, Medicxi announced a $40 million investment in D3 Bio, highlighting its commitment to supporting innovative biotech companies. Additionally, the firm closed a €200 million secondary fund, led by Pantheon and co-led by LGT Capital Partners, which provides liquidity for earlier fund LPs while retaining portfolio companies.
Since the last fundraise, Medicxi has realized over $1 billion across its portfolio, demonstrating its successful investment strategy. The firm has co-founded 16 new companies and achieved over 20 positive clinical data readouts, further solidifying its reputation in the biotech investment space.
What are Medicxi's investment criteria?
Medicxi focuses on early-stage biotech companies that have achieved clinical proof-of-concept. The firm looks for companies that are preparing for pivotal studies and regulatory approvals, emphasizing an asset-centric financing model.
How can startups apply or pitch to Medicxi?
Startups can reach out to Medicxi via email at investor@medicxi.com. It is advisable to include a detailed pitch deck that outlines the company's vision, product development stage, and market potential.
What makes Medicxi different from other venture capital firms?
Medicxi's asset-centric approach minimizes governance complexities and allows founders to focus on their product visions. The firm has a strong network of pharmaceutical partners, which enhances exit pathways and validation for portfolio companies.
What is Medicxi's geographic scope?
Medicxi primarily invests in Europe and the United Kingdom, focusing on biotech and healthcare sectors within these regions.
What is Medicxi's fund size and check size?
Medicxi's latest fund, Medicxi V, has a size of approximately $581 million. The firm invests across various stages, with check sizes tailored to the specific needs of the companies it supports.
What type of post-investment involvement does Medicxi have?
Medicxi provides strategic guidance throughout the drug development process, leveraging its industry expertise and relationships with pharmaceutical partners to enhance the success of its portfolio companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.